Medifast (Medifast) ROCE %

: 16.24% (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medifast's annualized ROCE % for the quarter that ended in Dec. 2023 was 16.24%.

Medifast ROCE % Historical Data

The historical data trend for Medifast's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medifast Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

81.15

95.83

109.98

91.51

64.34

Medifast Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %																74.96	117.22	78.65	49.32	16.24

Medifast ROCE % Calculation

Medifast's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	126.402	/	( ( (316.213 - 140.894)	+	(309.908 - 92.3) )	/ 2 )
	=	126.402	/	( (175.319	+	217.608)	/ 2 )
	=	126.402	/	196.4635
	=	64.34 %

Medifast's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	34.704	/	( ( (320.019 - 110.112)	+	(309.908 - 92.3) )	/ 2 )
	=	34.704	/	( ( 209.907	+	217.608 )	/ 2 )
	=	34.704	/	213.7575
	=	16.24 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Medifast (NYSE:MED) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medifast ROCE % Related Terms

Thank you for viewing the detailed overview of Medifast's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Medifast (Medifast) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Personal Services » Medifast Inc (NYSE:MED) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MED:Mexico MDF:Germany MDF:Germany

Address

100 International Drive, Baltimore, MD, USA, 21202

Website

https://www.medifastinc.com

Medifast Inc is a United states based company that produces, distributes and sells products concerning weight loss, weight management, and healthy living. The company generates its revenue from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other consumable health and nutritional products.

Executives

Jeffrey J Brown	director	19900 MACARTHUR BLVD, SUITE 570, IRVINE CA 92612
Andrea B Thomas	director	C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Michael A. Hoer	director	MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Scott Schlackman	director	3600 CRONDALL LANE, OWINGS MILLS MD 21117
Hallquist Constance J.	director	3600 CRONDALL LANE, OWINGS MILLS MD 21117
Elizabeth A. Geary	director	C/O MEDIFAST, INC., 100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Daniel R Chard	director, officer: Chief Executive Officer	NU SKIN ENTERPRISES, INC., 75 WEST CENTER STREET, PROVO UT 84601
Jonathan Barrett Mackenzie	officer: VP, Finance & CAO	100 INTERNATIONAL DRIVE, BALTIMORE MD 21202
Kevin G Byrnes	director	C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Michael C Macdonald	director	C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
James P. Maloney	officer: Chief Financial Officer	415 HOLIDAY DRIVE, PITTSBURGH PA 15220
Ming Xian	director	MEDIFAST, INC., 100 INTERNATIONAL DRIVE, 18TH FLOOR, BALTIMORE MD 21202
Carl E Sassano	director	C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117
Joseph P Kelleman	officer: (Interim) CFO	3600 CRONDALL LANE, OWINGS MILLS MD 21117
Timothy G Robinson	officer: Chief Financial Officer	C/O MEDIFAST, INC., 3600 CRONDALL LANE, OWINGS MILLS MD 21117